Nitroreductase: a prodrug-activating enzyme for cancer gene therapy.

Nitroreductase: a prodrug-activating enzyme for cancer gene therapy.

1. The prodrug CB1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide) is activated by Escherichia coli nitroreductase (NTR) to a potent DNA-crosslinking agent. 2. Virus-mediated expression of NTR in tumour cells sensitizes them to CB1954 in vitro and in vivo, providing the basis for a strategy of cancer ge...

Bibliográfalaš dieđut
Váldodahkkit:	Searle, P, Chen, M, Hu, L, Race, P, Lovering, A, Grove, J, Guise, C, Jaberipour, M, James, N, Mautner, V, Young, L, Kerr, D, Mountain, A, White, SA, Hyde, E
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2004

Geahča maid

The nitroreductase/CB1954 enzyme-prodrug system.
Dahkki: Green, N, et al.
Almmustuhtton: (2004)

Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer.
Dahkki: Palmer, D, et al.
Almmustuhtton: (2004)

Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector.
Dahkki: Chen, M, et al.
Almmustuhtton: (2004)

Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil.
Dahkki: Palmer, D, et al.
Almmustuhtton: (2003)

Inhibition of NF-kappaB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy.
Dahkki: Palmer, D, et al.
Almmustuhtton: (2005)

Virus-directed, Enzyme Prodrug Therapy with Nitroimidazole Reductase: A Phase I and Pharmacokinetic Study of its Prodrug, CB1954
Dahkki: Chung-Faye, G, et al.
Almmustuhtton: (2001)

LEAPT: lectin-directed enzyme-activated prodrug therapy.
Dahkki: Robinson, M, et al.
Almmustuhtton: (2004)

Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector.
Dahkki: Green, N, et al.
Almmustuhtton: (2003)

Lectin-directed enzyme activated prodrug therapy (LEAPT): Synthesis and evaluation of rhamnose-capped prodrugs.
Dahkki: Garnier, P, et al.
Almmustuhtton: (2010)

Development of a novel enzyme/prodrug combination for gene therapy of cancer: horseradish peroxidase/indole-3-acetic acid.
Dahkki: Greco, O, et al.
Almmustuhtton: (2000)

The horseradish peroxidase/indole-3-acetic acid combination for enzyme prodrug therapy: RROM in vitro to in vivo.
Dahkki: Tupper, J, et al.
Almmustuhtton: (2002)

Quinone oxidoreductase-2-mediated prodrug cancer therapy.
Dahkki: Middleton, MR, et al.
Almmustuhtton: (2010)

Responsive supramolecular prodrug nanoparticles for cancer therapy
Dahkki: Chen, Hongzhong
Almmustuhtton: (2017)

Horseradish peroxidase-mediated gene therapy: choice of prodrugs in oxic and anoxic tumor conditions.
Dahkki: Greco, O, et al.
Almmustuhtton: (2001)

An activatable NIR fluorescent rosol for selectively imaging nitroreductase activity
Dahkki: Klockow, JL, et al.
Almmustuhtton: (2019)

Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy
Dahkki: Ding, Chendi, et al.
Almmustuhtton: (2023)

Selective thrombosis of tumor for enhanced hypoxia-activated prodrug therapy
Dahkki: Ma, Zhaoyu, et al.
Almmustuhtton: (2022)

Halogenated indole-3-acetic acids as oxidatively activated prodrugs with potential for targeted cancer therapy.
Dahkki: Rossiter, S, et al.
Almmustuhtton: (2002)

A nitroreductase-activatable metabolic reporter for covalent labeling of pathological hypoxic cells in tumorigenesis
Dahkki: Wang, Zhimin, et al.
Almmustuhtton: (2025)

Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
Dahkki: Denmeade, SR, et al.
Almmustuhtton: (2003)

Pt(IV) anticancer prodrugs and liposomal encapsulation
Dahkki: Marsh, L
Almmustuhtton: (2022)

On the design of a bacterial cell-based prodrug enzyme system for HER2 positive breast cancer:
Dahkki: Kuziez, A
Almmustuhtton: (2023)

Light-responsive prodrug-based supramolecular nanosystems for site-specific combination therapy of cancer
Dahkki: Phua, Fiona Soo Zeng, et al.
Almmustuhtton: (2020)

A semiconducting polymer nano-prodrug for hypoxia-activated synergetic photodynamic cancer therapy
Dahkki: Cui, Dong, et al.
Almmustuhtton: (2019)

Self-assembled oxaliplatin(IV) prodrug-porphyrin conjugate for combinational photodynamic therapy and chemotherapy
Dahkki: Lim, Wei Qi, et al.
Almmustuhtton: (2021)

5-Fluoroindole-3-acetic acid: a prodrug activated by a peroxidase with potential for use in targeted cancer therapy.
Dahkki: Folkes, L, et al.
Almmustuhtton: (2002)

The tuberculosis prodrug isoniazid bound to activating peroxidases.
Dahkki: Metcalfe, C, et al.
Almmustuhtton: (2008)

Colchicine Prodrugs and Codrugs: Chemistry and Bioactivities
Dahkki: Ghawanmeh, Abdullah A., et al.
Almmustuhtton: (2018)

H2-driven reduction of flavin by hydrogenase enables cleaner operation of nitroreductases for nitro-group to amine reductions
Dahkki: Ramirez, MA, et al.
Almmustuhtton: (2022)

Hypoxia-driven elimination of thiopurines from their nitrobenzyl prodrugs.
Dahkki: Thomson, P, et al.
Almmustuhtton: (2007)

Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo
Dahkki: Dhar, Shanta, et al.
Almmustuhtton: (2011)

Starvation, ferroptosis, and prodrug therapy synergistically enabled by a cytochrome c oxidase like nanozyme
Dahkki: Cao, Changyu, et al.
Almmustuhtton: (2022)

Cancer-targeted design of bioresponsive prodrug with enhanced cellular uptake to achieve precise cancer therapy
Dahkki: Liang, Yuanwei, et al.
Almmustuhtton: (2019)

Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4.
Dahkki: Thomson, P, et al.
Almmustuhtton: (2006)

Catalytic antibodies for amide cleavage and prodrug activation
Dahkki: Fleck, Roman (Roman W.), 1966-
Almmustuhtton: (2005)

Design, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs
Dahkki: O'Connor, L, et al.
Almmustuhtton: (2016)

NIR-light-intensified hypoxic microenvironment for cascaded supra-prodrug activation and synergistic chemo/photodynamic cancer therapy
Dahkki: Chen, Hongzhong, et al.
Almmustuhtton: (2022)

Cell-permeable lanthanide-platinum(IV) anti-cancer prodrugs
Dahkki: Yao, K, et al.
Almmustuhtton: (2021)

Low-meeting phenytoin prodrugs in vitro and in vivo correlations
Dahkki: , MARTODIHARDJO, Suwaldi, et al.
Almmustuhtton: (1987)

Clinical advances of hypoxia-activated prodrugs in combination with radiotherapy
Dahkki: Mistry, I, et al.
Almmustuhtton: (2017)